



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم

بسم الله الرحمن الرحيم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



HANAA ALY



Correlation of Circulating Cathelcidin Level and Inflammatory Bowel Disease Activity

Thesis

*Submitted for Partial Fulfilment of Master Degree in
Gastroenterology & Hepatology*

By

Ahmed Farahat Saleh Hossam Eldin

MB.B.CH, Faculty of Medicine, Ain Shams University

Under supervision of

Prof. Dr. Nanees Ahmed Adel

Professor of Internal Medicine

Faculty of Medicine, Ain Shams University

Assist. Prof. Dr. Ahmed Samir Abo Halima

Assistant Professor of Internal Medicine

Faculty of Medicine, Ain Shams University

Assist. Prof. Dr. Hossam Samir Elbaz

Assistant Professor of Internal Medicine

Faculty of Medicine, Ain Shams University

*Faculty of Medicine
Ain Shams University*

2021

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سبحانك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدقة الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**,
the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Manees Adel**, Professor of Internal Medicine, Faculty of Medicine, Ain Shams University for her keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Assist. Prof. Dr. Ahmed Samir Abo Halima**, Assistant Professor of Internal Medicine, Faculty of Medicine, Ain Shams University, for his kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Assist. Prof. Dr. Hossam Samir Elbaz**, Assistant Professor of Internal Medicine, Faculty of Medicine, Ain Shams University, for her great help, active participation and guidance.*

Ahmed Farahat

List of Contents

Title	Page No.
List of Abbreviations.....	i
List of Tables	iii
List of Figures	iv
Introduction	1
Aim of the Work.....	3
Review of Literature	
Inflammatory Bowel Diseases	4
Cathelicidins.....	102
Patients and Methods.....	113
Results	121
Discussion	149
Summary	164
Conclusion	169
Recommendations	170
References	171
Arabic Summary	—

List of Abbreviations

Abb.	Full term
6-MP	6-mercaptopurine
AGA.....	American Gastroenterological Association
AIF.....	Apoptosis-inducing factor
ANCA	Anti Neutrophilic Cytoplasmic Antibody
ASCA	Anti-Saccharomyces cerevisiae antibodies
AZA.....	Azathioprine
BMPR	Bone morphogenetic protein.
C. Difficile	Clostridium Difficile
CBC	Complete blood picture
CD.....	Crohn's disease
CDAI	Crohn's Disease Activity Index
CRC	ColoRectal Carcinoma
CRP.....	C-reactive protein
DHFR	Dihydrofolate reductase
DSS.....	Dextran sulphate sodium
EEN	Exclusive enteral nutrition
EGD	Esophagogastroduodenoscopy
ELISA.....	Enzyme-linked immunosorbent assay
ESR	Erythrocyte Sedimentation Rate
FPRL1	Formyl peptide receptor-like 1
GI.....	Gastrointestinal
GMPS	Guanosine monophosphate synthetase.
GREs.....	Glucocorticoids -responsive elements
HBI	Harvey-Bradshaw index
HDL	High-density lipoprotein
HPRT.....	Hypoxanthine phosphoribosyl transferase

List of Abbreviations Cont...

Abb.	Full term
IBDs.....	Inflammatory bowel diseases
IFX.....	Inflixmab
IMPDH	Inosine monophosphate dehydrogenase
IOR	Induction of remission
LDL.....	Low-density lipoprotein
LL-37	Leucine-leucine-37
MAP	Mitogen-activated protein
mCRAMP	Mouse cathelicidin related antimicrobial peptide
MMF	Mycophenolate mofetil
MMX	Multimatrix
MOR	Maintenance of remission
MSCs	Mesenchymal Stem Cells
NO	Nitric Oxide
P-ANCA.....	Perinuclear antineutrophil cytoplasmic antibodies
PSC.....	Primary sclerosing cholangitis
SCD.....	Specific Carbohydrate Diet
TBMT	Thiopurine-S-methyltransferase
TGF-b1	Transforming growth factor-b1
TNF	Tumor necrosis factor
UC.....	Ulcerative colitis
UCEI	Ulcerative Colitis Endoscopic Index of Severity
WBC	White blood cell
WCE	Wireless Capsule Endoscopy

List of Tables

Table No.	Title	Page No.
Table (1):	The endoscopic subscore ranges from 0 to 3.	31
Table (2):	Ulcerative Colitis Endoscopic Index of Severity.....	32
Table (3):	(Crohn'sEIS) Crohn's disease index of severity.....	36
Table (4):	Generic preparations of Aminosalycelates.....	46
Table (5):	Possible functional effects and mechanisms of action of cathelicidins in different gastrointestinal disorders	110
Table (6):	Mayo Endoscopic Subscore to assess mucosal disease activity in UC patients (MES) range (0-3)...	117
Table (7):	Demographic data of the studied cases.....	123
Table (8):	Laboratory data of the studied cases.....	124
Table (9):	LL-37 level among studied cases.	125
Table (10):	Colonoscopy results among studied cases.	126
Table (11):	Severity of the disease in 40 IBD patients according to PMS for UC patients and HBI for CD. ..	127
Table (12):	Comparison between cases and control group regarding demographic data.....	129
Table (13):	Comparison between cases and control group regarding laboratory data.	131
Table (14):	Comparison between cases and control group as regard LL-37.	136
Table (15):	Correlation of LL-37 with the other studied parameters in 40 IBD patients.	140
Table (16):	Correlation of CRP with LL-37, PMS, albumin and Harvey Bradshaw index.	145
Table (17):	Correlation of LL-37 with sex, colonoscopy result, PMS, MES and HBI.	147

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Incidence of IBD around the world	6
Figure (2):	Anterior uveitis in a patient with Inflammatory Bowel Disease.	14
Figure (3):	Patient with inflammatory bowel disease with red nodular areas on the shins which are characteristic of Erythema Nodosum.....	14
Figure (4):	A) Radiograph reveals thumbprinting, B) Toxic megacolon	22
Figure (5):	Double-contrast barium enema.....	23
Figure (6):	Inflammatory changes in active Crohn's disease assessed by US	23
Figure (7):	B-mode transabdominal ultrasound in a patient with Crohn's disease of the right colon showing a hypoechoic bowel wall thickening and transmural inflammatory reaction and blind ending fistula (mes) in direction to the abdominal wall (abd wall).....	25
Figure (8):	Contrast-enhanced CT	25
Figure (9):	Spectrum of findings in active Crohn's disease.....	26
Figure (10):	Active Crohn's disease in the terminal ileum evaluated by MRI.....	27
Figure (11):	Endoscopic findings in ulcerative colitis.....	29
Figure (12):	Sigmoidoscopic view of moderately active ulcerative colitis.....	30
Figure (13):	Colonic pseudopolyps of a patient with intractable ulcerative colitis	30
Figure (14):	Colonoscopy demonstrates small discreet aphthous lesions	33

List of Figures Cont...

Fig. No.	Title	Page No.
Figure (15):	Colonoscopy shows linear ulcers that can course for several centimeters along the longitudinal axis of the colon in Crohn's disease.	34
Figure (16):	Colonoscopy in Crohn's disease demonstrates the characteristic patchy erythema (left panel) and ulceration (right panel) that occur next to areas of normal mucosa.....	34
Figure (17):	The initial metabolism of 6-mercaptopurine occurs along the competing routes catalyzed by thiopurine methyltransferase (TPMT), xanthine oxidase (XO), and hypoxanthine phosphoribosyltransferase (HPRT).....	51
Figure (18):	Available biologic therapies for inflammatory bowel disease.	62
Figure (19):	Several new drugs — vedolizumab, anti-MAdCAM1 antibodies and etrolizumab — target T-cell homing and retention as a therapeutic target in IBD	72
Figure (20):	Gross appearance of the colon from a patient with pseudomembranous colitis	80
Figure (21):	Plain film of the abdomen from a patient with toxic megacolon associated with <i>Clostridioides</i> (formerly <i>Clostridium</i>) <i>difficile</i> infection	83
Figure (22):	Remission induction treatment for mildly-to-moderately active distal UC	97
Figure (23):	Remission induction treatment for mildly-to-moderately active extensive.....	98

List of Figures Cont...

Fig. No.	Title	Page No.
Figure (24):	Remission induction treatment for severely active UC.....	99
Figure (25):	Maintenance treatment for UC in remission	99
Figure (26):	Remission induction treatment for active CD	100
Figure (27):	Treatment for intestinal complications of CD	101
Figure (28):	Maintenance treatment for CD in remission	101
Figure (29):	Categorization of IBD patients according to sex.	123
Figure (30):	Categorization of inflammatory bowel disease patients according to colonoscopy results.	126
Figure (31):	Categorization of severity for patients with ulcerative colitis according to partial Mayo score.....	128
Figure (32):	Categorization of severity for patients with ulcerative colitis according to partial Harvey-Bradshaw index.	128
Figure (33):	Comparison between cases and control group regarding age.....	130
Figure (34):	Comparison between cases and control group regarding sex.	130
Figure (35):	Comparison between cases and control group regarding Hb.	133
Figure (36):	Comparison between cases and control group regarding AST, ALT and ALP.	133

List of Figures Cont...

Fig. No.	Title	Page No.
Figure (37):	Comparison between cases and control group regarding total and direct bilirubin.....	134
Figure (38):	Comparison between cases and control group regarding creatinine level.....	134
Figure (39):	Comparison between cases and control group as regard Urea and ESR.....	135
Figure (40):	Comparison between cases and control group as regard CRP.	135
Figure (41):	Comparison between cases and control group as regard LL-37.....	137
Figure (42):	Receiver operating characteristic curve (ROC) for prediction of IBD cases.	138
Figure (43):	Receiver operating characteristic curve (ROC) for prediction of IBD cases according to CRP.....	139
Figure (44):	Receiver operating characteristic curve (ROC) for prediction of IBD cases according to LL-37.	139
Figure (45):	Positive correlation between LL-37 and AST.....	141
Figure (46):	Positive correlation between LL-37 and serum albumin.....	141
Figure (47):	Negative correlation between LL-37 and stool frequency.....	142
Figure (48):	Negative correlation between LL-37 and rectal bleeding.....	142
Figure (49):	Negative correlation between CRP and LL-37.....	143
Figure (50):	Negative correlation between LL-37 and Harvey Bradshaw index.	143

List of Figures Cont...

Fig. No.	Title	Page No.
Figure (51):	Negative correlation between LL-37 and Partial Mayo score.	144
Figure (52):	Negative correlation between CRP and LL-37.....	145
Figure (53):	Positive correlation between CRP and Partial Mayo score.	146
Figure (54):	Positive correlation between CRP and Harvey Bradshaw index.	146
Figure (55):	Correlation of LL-37 level and partial mayo score.....	148
Figure (56):	Correlation of LL-37 level and Mayo endoscopic score.....	148